WuXi Bi­o­log­ics IPO reaps $509M wind­fall; In­tel­lia strikes CRISPR pact with San Raf­faele

→  WuXi Bi­o­log­ics raised HK$3.8 bil­lion ($509 mil­lion) as it had set its sights on last month, of­fer­ing 193 mil­lion shares at HK$20.60 ($2.64). The Wuxi, Chi­na-based com­pa­ny will list on the Hong Kong Ex­change. Bo­fA Mer­rill Lynch, Mor­gan Stan­ley and Chi­na Mer­chants Se­cu­ri­ties are the joint bookrun­ners on the deal which is ex­pect­ed to price June 6, 2017.

→  Cam­bridge, Mass-based In­tel­lia has part­nered with San Raf­faele Uni­ver­si­ty in Italy. The two en­tered a three-year agree­ment to col­lab­o­rate on re­search us­ing In­tel­lia’s CRISPR/Cas9 genome edit­ing tech­niques to en­gi­neer new T Cell ther­a­pies to fight can­cer. In­tel­lia has been op­ti­miz­ing its gene edit­ing sys­tem in pre­clin­i­cal tri­als in hopes of de­vel­op­ing the ac­cu­ra­cy to cre­ate a one-time cure for dis­eases. This is the first ex­ter­nal part­ner­ship of the eX­tel­lia di­vi­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER